Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash & Equivalents (2020 - 2026)

Xeris Biopharma Holdings filings provide 6 years of Cash & Equivalents readings, the most recent being $111.0 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 55.04% to $111.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $111.0 million, a 55.04% increase, with the full-year FY2025 number at $111.0 million, up 55.04% from a year prior.
  • Cash & Equivalents hit $111.0 million in Q4 2025 for Xeris Biopharma Holdings, up from $91.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $122.0 million in Q4 2022 to a low of $46.1 million in Q3 2023.
  • Median Cash & Equivalents over the past 5 years was $65.0 million (2021), compared with a mean of $73.0 million.
  • Biggest five-year swings in Cash & Equivalents: soared 81.31% in 2022 and later crashed 51.57% in 2023.
  • Xeris Biopharma Holdings' Cash & Equivalents stood at $67.3 million in 2021, then soared by 81.31% to $122.0 million in 2022, then tumbled by 44.7% to $67.4 million in 2023, then grew by 6.19% to $71.6 million in 2024, then skyrocketed by 55.04% to $111.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $111.0 million (Q4 2025), $91.6 million (Q3 2025), and $59.3 million (Q2 2025) per Business Quant data.